References
- Passaro A , LazzariC, KarachaliouNet al. Personalized treatment in advanced ALK-positive non-small-cell lung cancer: from bench to clinical practice. Onco Targets Ther.9, 6361–6376 (2016).
- Shaw AT , KimDW, NakagawaKet al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med.368(25), 2385–2394 (2013).
- Solomon BJ , MokT, KimDWet al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med.371(23), 2167–2177 (2014).
- Marsilje TH , PeiW, ChenBet al. Synthesis, structure–activity relationships and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in Phase I and Phase II clinical trials. J. Med. Chem.56(14), 5675–5690 (2013).
- Friboulet L , LiN, KatayamaRet al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small-cell lung cancer. Cancer Discov.4(6), 662–673 (2014).
- Shaw AT , KimDW, MehraRet al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med.370(13), 1189–1197 (2014).
- Kim DW , MehraR, TanDSet al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicenter, open-label, Phase I trial. Lancet Oncol.17(4), 452–463 (2016).
- Shaw AT , KimTM, CrinòLet al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomized, controlled, open-label, Phase III trial. Lancet Oncol.18(7), 874–886 (2017).
- Crinò L , AhnMJ, De MarinisFet al. Multicenter Phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J. Clin. Oncol.34(24), 2866–2873 (2016).
- Metro G , TazzaM, MatocciRet al. Optimal management of ALK-positive NSCLC progressing on crizotinib. Lung Cancer106, 58–66 (2017).
- Zhu Q , HuH, WengDSet al. Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC. BMC Cancer17(1), 412 (2017).
- Brosnan EM , WeickhardtAJ, LuXet al. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small-cell lung cancer treated with the ALK inhibitor crizotinib. Cancer120(5), 664–674 (2014).
- European Medicines Agency. Zykadia, INN-ceritinib, Europa EU (2015). www.ema.europa.eu/docs/en_GB/…/WC500187504.pdf
- Arakawa H , OmoteS, TamaiI. Inhibitory effect of crizotinib on creatinine uptake by renal secretory transporter OCT2. J. Pharm. Sci.106(9), 2899–2903 (2017).
- Lau YY , GuW, LinTet al. Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects. J. Clin. Pharmacol.56(5), 559–566 (2016).
- Schaefer ES , BaikC. Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer. Cancer Manag. Res.8, 33–38 (2016).
- Nishio M , MurakamiH, HoriikeAet al. Phase I study of ceritinib (LDK378) in Japanese patients with advanced, anaplastic lymphoma kinase-rearranged non-small-cell lung cancer or other tumors. J. Thorac. Oncol.10(7), 1058–1066 (2015).
- Cho BC , KimDW, BearzAet al. ASCEND-8: a randomized Phase I study of ceritinib 450 mg or 600 mg taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small-cell lung cancer (NSCLC). J. Thorac. Oncol.12(9), 1357–1367 (2017).
- Gainor JF , TanDS, De PasTet al. Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib. Clin. Cancer Res.21, 2745–2752 (2015).